BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. “Amyotrophic Lateral Sclerosis” campaign wants to bring attention to this condition and analyse the variables that might affect its progression. In “The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis” M. Kelly et al. report the results of an exploratory, non-controlled, nondrug study that aimed to objectively monitor ALS patients at home, to explore novel disease progression markers.
Our Community of Practice
José Manuel García Domínguez, neurologist at Hospital General Universitario Gregorio Marañón in Madrid explains in simple terms what is Multiple Sclerosis.
